Raphael Pharmaceutical (RAPH) Operating Expenses (2020 - 2024)

Raphael Pharmaceutical has disclosed Operating Expenses across 5 years of filings, most recently posting $394000.0 for Q4 2024.

• Operating Expenses for Q4 2024 came in at $394000.0, up 632.43% year-over-year; the trailing twelve-month figure through Sep 2025 was $394000.0 (down 62.15% YoY), and the FY2025 annual result was $648000.0, down 12.79% from the prior year.
• Operating Expenses came in at $394000.0 for Q4 2024 at Raphael Pharmaceutical, up from $319000.0 in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.4 million in Q3 2022 to a low of -$74000.0 in Q4 2023.
• The 5-year median for Operating Expenses is $389500.0 (2021), against an average of $458277.8.
• Across the five-year window, Operating Expenses plunged 106.7% in 2023 and soared 632.43% in 2024, its largest moves.
• Raphael Pharmaceutical's Operating Expenses stood at $227000.0 in 2020, then surged by 152.86% to $574000.0 in 2021, then surged by 92.33% to $1.1 million in 2022, then tumbled by 106.7% to -$74000.0 in 2023, then jumped by 632.43% to $394000.0 in 2024.
• The last three Operating Expenses figures came in at $394000.0 (Q4 2024), $319000.0 (Q3 2024), and $249000.0 (Q2 2024), per Business Quant data.